While the news about mechanistic therapies in neurodegeneration has been generally rather glum, particularly with the failure of BACE trials for Alzheimer's disease, in my view, easily the most important development in neurodegeneration research in 2017 has been introduction of successful gene based therapies for spinal muscular atrophy which is caused by mutations in the SMN1 gene (1, 2) . One report, a phase 1/2 trial, depends on injection of adenoassociated virus carrying SMN cDNA (1) and the other, a report of a phase 3 trial, depends upon intrathecal injection of an antisense oligonucleotide which corrects the misplicing of the SMN2 pseudogene such that this pseudogene produces enough active protein for the defect to be corrected (2) . The phase 3 trial of the antisense oligonucleotide was successful to the extent that the trial was halted early. Remarkably, this therapy is now in clinical practice. This is clearly important for patients with SMA though discussions over the price of the therapy have somewhat soured the elation. Its wider importance however, is that it is the first mechanistic therapy for a neurodegenerative disease and, while this therapeutic approach for SMA uniquely depends on the activation of a pseudogene, it bodes well for oligonucleotide strategies for other genetic diseases: APP for Alzheimer's disease, MAPT for frontotemporal dementia and progressive supranuclear palsy, synuclein for Parkinson's disease, huntingtin for Huntington's disease and so on. Let us hope that this breakthrough is the first swallow of a treatment spring for all these devastating diseases.
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The Nobel Prize for Chemistry this year went to Jacques Dubochet, Joachim Frank and Richard Henderson for their work developing the cryo-e.m.
technology. This year, the power of this approach has been demonstrated by the identification of structures for the structure of the paired helical filaments of tangle (3) and for amyloid fibrils of plaques (4) . In both cases, we already know that there are multiple different structures which are associated with different clinical features (3) (4) (5) .
For many years, we have lacked biomarkers which are effective and easily accessible markers of neurodegeneration. PET and CSF markers can be useful of course, but a blood biomarker of neurodegeneration would have the potential to transform the field. Neurofilament light protein (NFL) in blood seems to be such a marker. It seems likely that its level increases in blood in all diseases where there is ongoing axonal damage. The use of this marker has been reported in Huntington's disease and in Alzheimer's disease (6, 7) but there are other reports submitted or "in press" which indicate this is a general marker of damage. This marker offers the hope of being able to measure changes in the rate of neurodegeneration and of assessing treatment effects in a systematic, inexpensive and consistent fashion. It, therefore, has the potential to revolutionise clinical trials.
Perhaps the biggest advance in genetics this year has been from the release of the data from the GTEx project (8) . This online resource maps gene expression with genotype across all the major tissues and will be a Rosetta Stone for the interpretation of genome wide association studies. As single nucleotide polymorphisms are associated with disease, these can be dialed up to see which gene, which transcript and which tissue they alter expression in. The importance of data integration between genetic and expression data was beautifully illustrated by the work showing that many of the Alzheimer loci were targets of the microglial transcription factor PU. 
